Loading clinical trials...

tACS Treatment for Cognitive Impairments in Methamphetamine Addicts | Clinical Trials | Clareo Health

COMPLETEDNA

tACS Treatment for Cognitive Impairments in Methamphetamine Addicts

NCT06292156•Beijing HuiLongGuan Hospital

Summary

1. To evaluate the cognitive function of methamphetamine Patients. 2. Investigate the pathological mechanism of methamphetamine patients from the aspects of EEG and biology; 3. The investigators investigated the effects of transcranial alternating current stimulation (tACS) on cognitive impairments in methamphetamine patients

Eligibility

Age

18 - 55 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Clinical diagnosis diagnosis of methamphetamine use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
•None of participants had mixed use of other drugs
•None of participants had physical disability
•None of participants had acute physical or mental illness, hallucinations, acute withdrawal symptoms
•None of participants were receiving any medical treatment

Exclusion Criteria

•Intracranial hypertension
•Cranial defects
•Tumors
•Serious physical illnesses (e.g., cardiovascular, liver, kidney, gastrointestinal disorders)
•Infectious diseases
•Immune system disorders

Locations (1)

Xin Hua Drug Rehabilitation Center

Mianyang, China

Key Dates

Start Date

December 30, 2023

Primary Completion Date

December 30, 2024

Completion Date

December 30, 2024

Last Updated

December 19, 2025

Enrollment

ACTUAL participants

Conditions

Methamphetamine Abuse

Interventions

Theta treatment group

DEVICE

Sham control group

DEVICE

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799

Methamphetamine-dependenceMethamphetamine Abuse

View study

COMPLETEDNA

Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics

NCT04706624

Methamphetamine AbuseOpioid-use Disorder+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

tACS Treatment for Cognitive Impairments in Methamphetamine Addicts

Inclusion Criteria

Exclusion Criteria

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics

rTMS for Stimulant Use Disorders

Demonstration of a Digital Care Program for Methamphetamine Use Disorder

Digital Therapeutics Smartphone Application for Methamphetamine Use Disorder

Depression Intervention Among Gay and Bisexual Men Receiving Treatment for Methamphetamine Use